ClinicalTrials.gg
TerminatedNCT04855591Updated Dec 1, 2021

A Trial of SHR-1703 in Healthy Subjects

A Phase 1 interventional study of SHR-1703 and Placebo in Asthma, sponsored by Atridia Pty Ltd.. Terminated at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-01.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Why this study was terminated
Adjustment of the clinical development plan for this product globally

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 6 under way, 2 of them phase 3. Asthma · Jiangsu HengRui Medicine Co., Ltd..

Enrollment
15th of 15
1 · median 84
Started
2021
with 4 others
Phase 1
7 of 15
1 open now
Registered
4th of 15
by date

Among the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., this one is the 15th largest by enrollment, is one of 5 that started in 2021, is one of 7 in phase 1, and was the 4th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

5 of the 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Asthma by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics and immunogenicity of subcutaneous administered SHR-1703 in healthy subjects.

Read the detailed description

The study will consist of one dose esclation part with a total of 3 dose levels. The Subjects will be randomized to receive SHR-1703 as reflected by the guiding principle for the dose esclation/expansion phase. Each dose group includes a screening period, a baseline period, an observational period, and a safety follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy Caucasian subjects, male and female, 18 to 55 years of age, inclusive;
  2. Body weight ≥45 kg (Both male and female), (BMI) between ≥19.0 and ≤29.9 kg/m2, inclusive;
  3. No abnormalities in medical history, general physical examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry and coagulation function) and at the investigator's discretion during screening and baseline.
  4. Men and women of (WOCBP) must agree to take effective methods and have no plan to have a child from signing the consent form to 30-days after last scheduled follow-up visit.

Exclusion criteria

Exclusion Criteria:

  1. Known history or suspected of being allergic to the study drug.
  2. Positive virus (HBsAg), virus (HCV-Ab), (HIV-Ab) at screening.
  3. Participation in clinical trials of other drugs or medical devices within 3 months prior to screening or within 5 half-lives of any drugs during screening visit, or in the follow-up period of a clinical study whichever is longer
  4. Use of any medicine within 4-weeks prior to the IP administration
  5. Blood donation or loss of more than 400 mL of blood within 1 month of screening; or received blood transfusion within 2 months before screening.
  6. Live (attenuated) vaccination within 1 month before screening or plan to be vaccinated
  7. Severe injuries or major surgeries within 6 months before screening or plan to do surgeries during the trial
  8. Patients with known or suspected parasitic infection within 6 months before screening
  9. Either , AST, ALP, GGT or total level exceeds (ULN) at screening or baseline visits (confirmed by a single repeat, as per investigator's judgment)
  10. More than 5 cigarettes daily (or products with equivalent amount of nicotine) for 3 months prior to screening.
  11. History of alcohol abuse within 3 months prior to the IP administration
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    SHR-1703 Dose Level 1

    Dose level 1 SHR-1703

    Drug: SHR-1703 · Drug: Placebo

  • Experimental
    SHR-1703 Dose Level 2

    Dose level 2 SHR-1703

    Drug: SHR-1703 · Drug: Placebo

  • Experimental
    SHR-1703 Dose Level 3

    Dose level 3 SHR-1703

    Drug: SHR-1703 · Drug: Placebo

  • Experimental
    SHR-1703 Dose Level 4 (optional)

    Dose level 4 SHR-1703 Additional dose escalations, as determined by the SMC depend on PK and safety data review

    Drug: SHR-1703 · Drug: Placebo

Interventions

  • SHR-1703 will be administered subcutaneously

  • DrugPlacebo

    Placebo of SHR-1703 will be administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Adverse events

    Incidence and severity of adverse events

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

Secondary outcomes

  1. Pharmacokinetics-AUC0-last

    Area under the concentration-time curve from time 0 to last time point after SHR-1703 administration

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  2. Pharmacokinetics-AUC0-inf

    Area under the concentration-time curve from time 0 to infinity after SHR-1703 administration

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  3. Pharmacokinetics-Tmax

    Time to Cmax of SHR-1703

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  4. Pharmacokinetics-Cmax

    Maximum observed concentration of SHR-1703

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  5. Pharmacokinetics-CL/F

    Apparent clearance of SHR-1703

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  6. Pharmacokinetics-Vz/F

    Apparent volume of distribution during terminal phase of SHR-1703

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  7. Pharmacokinetics-t1/2

    Terminal elimination half-life of SHR-1703

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  8. Pharmacodynamics-Eosinophils

    Absolute eosinophils account and change from baseline in percentage

    Time frame: Start of Treatment to end of study (approximately 34 weeks)

  9. Anti-drug-antibody

    The percentage of subjects with positive ADA titers over time for SHR-1703

    Time frame: Start of Treatment to week 22 after IP administration

07

Study locations

1 site
  • Nucleus Network
    Brisbane, Queensland, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Sep 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2021
First posted
Apr 22, 2021
StartActual
Jun 14, 2021
Primary completionActual
Sep 13, 2021
CompletionActual
Nov 18, 2021
Last update
Dec 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04855591
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Jun 14, 2021
Primary completion
Sep 13, 2021
Completion
Nov 18, 2021
Last update
Dec 1, 2021

Study contacts

Dr Richard Friend
principal investigator · Nucleus Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1703

Start the discussion